Abstract
Surgical technique is the most important factor for patients’ long-term outcome. There has been a long debate about the extent of lymph node dissection between Asian surgeons and Western surgeons. Japanese and Korean surgeons believe that wider lymph node dissection, e.g., D2 dissection, is necessary for the better outcome. On the other hand, Western surgeons insisted that there is no evidence for the benefit of D2 dissection over less lymph node dissection, e.g., D1 dissection, based on the negative results of two European studies. MRC ST01 trial compared D1 surgery and D2 surgery in the 1990s and found the 5-year overall survival rate was similar (35%, 33%, respectively). The postoperative morbidity (28% vs 46%) and mortality (6.5% vs 13%) were higher with D2 surgery [1, 2]. Dutch D1D2 study compared the outcomes of D1 surgery with D2 surgery and reported that the 5-year overall survival rate was not different, that is, 34%, 33%, respectively [3]. However, 15-year follow-up data demonstrated the gastric cancer-related death rate was lower in patients with D2 dissection than those with D1 dissection (37% vs 48%) [4]. At present, D2 resection is recommended for advanced gastric cancer, including the USA and Europe [5, 6].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995–9.
Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer. 1999;79:1522–30.
Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.
Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15 year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.
Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;(Suppl 6):vi57–63.
NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 3.2016.
Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta analysis of randomized trials. J Clin Oncol. 1993;11:1441–7.
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059–64.
Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol. 2000;11:837–43.
Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597–608.
Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21–7.
GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.
Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.
Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15(8):886–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Germany, part of Springer Nature
About this chapter
Cite this chapter
Oh, DY., Bang, YJ. (2019). Adjuvant Treatment for Gastric Cancer. In: Noh, S., Hyung, W. (eds) Surgery for Gastric Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45583-8_30
Download citation
DOI: https://doi.org/10.1007/978-3-662-45583-8_30
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45582-1
Online ISBN: 978-3-662-45583-8
eBook Packages: MedicineMedicine (R0)